Post hoc analyses presented at the 2021 virtual American Society of Clinical Oncology (ASCO) annual meeting showed that the overall survival benefit with frontline avelumab (Bavencio) maintenance was ...

Adding avelumab to best supportive care following chemo in advanced UC significantly improved OS compared with best supportive care alone. Following chemotherapy for advanced urothelial carcinoma, ...

Please provide your email address to receive an email when new articles are posted on . A randomized phase 3 trial designed to evaluate avelumab as first-line maintenance therapy for patients with ...

US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck KgaA ...

The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with ...

Today's approval of avelumab (Bavencio, EMD Serono) by the US Food and Drug Administration (FDA) is the first for a treatment of Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.

Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell ...

This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

Avelumab plus cabozantinib has shown preliminary clinical activity and an acceptable safety profile in metastatic clear cell RCC, according to researchers. The combination of avelumab and cabozantinib ...

The clinical experts indicated that avelumab could be used either as a first treatment or after chemotherapy, but should ideally be used as early as possible in the treatment pathway for maximum ...

Please provide your email address to receive an email when new articles are posted on . Grade 3 or higher adverse events occurred in a lower proportion of patients after a year of treatment. Results ...

The appraisal committee considered evidence submitted by Merck, a review of this submission by the evidence review group (ERG), NICE's technical engagement response form, and responses from ...